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Abstract
Background
Poikiloderma is defined as a chronic skin condition presenting with a
combination of punctate atrophy, areas of depigmentation, hyperpigmentation
and telangiectasia. In a variety of hereditary syndromes such as Rothmund–
Thomson syndrome (RTS), Clericuzio-type poikiloderma with neutropenia
(PN) and Dyskeratosis Congenita (DC), poikiloderma occurs as one of the
main symptoms. Here, we report on genotype and phenotype data of a cohort
of 44 index patients with RTS or related genodermatoses.
Methods
DNA samples from 43 patients were screened for variants in the 21 exons of
the RECQL4 gene using PCR, SSCP-PAGE analysis and/or Sanger sequencing.
Patients with only one or no detectable mutation in the RECQL4 gene were
additionally tested for variants in the 8 exons of the USB1 (C16orf57) gene by
Sanger sequencing. The effect of novel variants was evaluated by phylogenic
studies, single-nucleotide polymorphism (SNP) databases and in silico analyses.
Results
We identified 23 different RECQL4 mutations including 10 novel and one
homozygous novel USB1 (C16orf57) mutation in a patient with PN. Moreover,
we describe 31 RECQL4 and 8 USB1 sequence variants, four of them being novel
intronic RECQL4 sequence changes that may have some deleterious effects on
splicing mechanisms and need further evaluation by transcript analyses.
Conclusion
The current study contributes to the improvement of genetic diagnostic strate-
gies and interpretation in RTS and PN that is relevant in order to assess the
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patients’ cancer risk, to avoid continuous and inconclusive clinical evaluations
and to clarify the recurrence risk in the families. Additionally, it shows that
the phenotype of more than 50% of the patients with suspected Rothmund–
Thomson disease may be due to mutations in other genes raising the need for
further extended genetic analyses.
Introduction
Rothmund–Thomson syndrome (RTS, OMIM #268400)
is a rare, heterogeneous autosomal recessive genodermato-
sis due to biallelic mutations in the RECQL4 gene
(OMIM #603780) in about 66% of patients (Cabral et al.
2008; Larizza et al. 2010). The exact prevalence of RTS is
still unknown, and only around 400 cases have been
described in the literature so far (Larizza et al. 2013,
2010). The diagnostic hallmark of RTS is chronic poikilo-
derma (Larizza et al. 2010) that arises during the first
2 years of life, even though late onset of poikiloderma has
also been reported (Kumar et al. 2007). Other clinical fea-
tures include skeletal abnormalities (e.g., short stature,
frontal bossing, saddle nose, short fingers, radial ray
defects), alopecia, sparse or missing eyelashes and/or eye-
brows, photosensitivity, juvenile cataracts, premature
aging and a predisposition to malignancies, especially to
osteosarcoma and skin cancers (squamous and basal cell
carcinomas) (Larizza et al. 2010; Wang et al. 2001; Zils
et al. 2015). On the basis of clinical and molecular analy-
sis, two forms of RTS have been characterized: RTS type
I, presenting with typical poikiloderma and juvenile catar-
acts without RECQL4 mutations (Siitonen et al. 2009;
Wang et al. 2001) and RTS type II with poikiloderma
and an increased risk for osteosarcoma caused by deleteri-
ous mutations in RECQL4 (Larizza et al. 2013; Wang
et al. 2003). Differential diagnoses of RTS are dyskeratosis
congenita (DC) and poikiloderma with neutropenia (PN)
(all of them causing poikiloderma at young age) as well
as other rare genodermatoses with a telangiectatic
component (Bloom syndrome, Werner syndrome) and
other diseases with mutations in the RECQL4 gene such
as RAPADILINO and Baller–Gerold syndrome (BGS)
(Larizza et al. 2010).
The RECQL4 gene is located on chromosome 8q24.3
spanning 21 exons and belongs to the protein family of
DNA helicases that are important in maintaining genomic
integrity (Croteau et al. 2012b; Lu et al. 2014). It encodes
the ATP-dependent DNA helicase Q4 (RecQ protein-like
4), a 133-kDa protein consisting of 1208 amino acids.
RECQL4 participates in base excision repair, nucleotide
excision repair, homologous recombination and in the
initiation of DNA replication (Croteau et al. 2012b; Liu
2010). Moreover, it plays a role in telomere (Ghosh et al.
2012) as well as in mitochondrial DNA maintenance
(Croteau et al. 2012a) and interacts with the tumor
suppressor p53 (De et al. 2012).
Mutations in the USB1 (C16orf57) (U6 snRNA
biogenesis 1, OMIM #613276) gene give rise to
autosomal-recessive Clericuzio-type poikiloderma with
neutropenia (PN, OMIM #604173), characterized by
early-onset poikiloderma (appearing in the first year of
life), nail abnormalities, palmoplantar hyperkeratosis,
skeletal defects as well as noncycling neutropenia and
recurrent sinopulmonary infections (Colombo et al.
2012). The rash is eczematous and starts peripherally
before spreading centrally to the trunk and face. Further-
more, individuals with this very rare disorder may present
with craniofacial dysmorphism, carious teeth and
postnatal growth delay (Farruggia et al. 2014).
The USB1 gene is localized on 16q21, contains 7 exons
spanning 22 kb and encodes a 265-amino acid protein
with 5 helical domains that is highly conserved among
vertebrates. Although the function of the USB1 protein
remains still unclear, there is evidence that it is essential
for the processing and stability of U6 small nucleolar
RNA with a pivotal role in RNA splicing (Mroczek et al.
2012; Shchepachev et al. 2012).
Here, we present genotype and phenotype data of a
cohort of 44 index patients with clinically suspected RTS
or related genodermatoses. We delineate the spectrum of
pathogenic mutations including 10 novel RECQL4 muta-
tions and one homozygous novel USB1 mutation as well
as of 31 and 8 different gene variants respectively.
Patients and Methods
Ethical compliance
The local Swiss Ethics Committee on research involving
humans approved this study.
Patient cohort
A total of 44 (22 females, 22 males; age range 0.2–
39 years) unrelated, ethnically diverse patients with clini-
cal suspicion of RTS or related genodermatoses and
referred to our laboratory from 2005 to 2014 were
included in this study. Appropriate informed consent for
genetic testing was obtained from the patients or their
parents.
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Methods
DNA samples from 43 patients (numbered consecutively
from 1 through 43) were screened for variants in the 21
exons (including boundaries for exon/intron 3, 4, 6, 9, 12
and entire sequences of intron 1, 2, 5, 7, 8, 11, 13–20) of
the RECQL4 gene using PCR, SSCP-PAGE analysis and/or
Sanger sequencing as described before (Gallati et al.
2009). Additionally, patients with only one or no detect-
able mutation in the RECQL4 gene as well as patient No
44, who presented with a classic PN phenotype, were
tested for variants in the coding region of the USB1 gene
(7 exons including exon/intron boundaries) by Sanger
sequencing. Primer sequences and PCR conditions are
available upon request. Mutation positions are given
according to the Reference sequences for RECQL4 (Gen-
Bank NM_004260.3) and USB1 (GenBank NM_024598.3),
numbering starting at the A of the ATG initiation codon,
and nomenclature is according to the Human Genome
Variation Society (www.hgvs.org/mutnomen/). The effect
of novel variants was evaluated by phylogenic studies,
single nucleotide polymorphism (SNP) databases (1000
genomes (http://browser.1000genomes.org/index.html),
Exome Variant Server (http://evs.gs.washington.edu/EVS/)
and ExAC Browser (http://exac.broadinstitute.org)) and
in silico analyses using MutPred (http://mutpred.mut
db.org), PredictSNP (http://loschmidt.chemi.muni.cz/pre
dictsnp), SNPs&GO (http://snps-and-go.biocomp.unibo.
it/snps-and-go/), PolyPhen-2 (http://genetics.bwh.har
vard.edu/pph2/) and Provean (http://provean.jcvi.org).
The variant data and phenotypes were registered and are
available at http://databases.lovd.nl/shared/genes/RECQL4
and http://www.ncbi.nlm.nih.gov/clinvar/?term=USB1%
5Bgene%5D. Statistical analyses have been performed
using chi-squared statistic and Fisher’s exact test.
Results
RECQL4 analyses
Figure 1 summarizes the RECQL4 mutation spectrum of
our patient cohort. Overall, 23 different RECQL4 muta-
tions were identified in 18 (42%) out of 43 index patients
(patient No 44 was solely tested for mutations in the
USB1 gene based on high clinical suspicion of PN). Two
patients were found to be homozygous due to parental
consanguinity, 10 patients showed heterozygosity for two
and one patient for three different mutations and in 5
patients only one deleterious sequence change was detect-
able. As illustrated in Figure 1, 13 of the identified muta-
tions are already listed in the Human Gene Mutation
Database (HGMD, http://www.biobase-international.com)
and/or reported in publications, 5 of them presenting as
recurrent sequence changes. The remaining 10 sequence
Figure 1. Scheme of the RECQL4 Gene. Boxes and introns indicate exons by lines. Yellow identifies the exons with identified mutations, white
the exons without mutations. Red characters = nonsense mutations, blue = frameshift mutations, purple = inframe mutations, green = missense
mutations. RECQL4 GenBank NM_004260.3.
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Table 1. Allele frequencies of RECQL4 and USB1 (C16orf57) variants.
RECQL4
exon (E)
intron (I) dpSNP ID Variant
Frequencies
%, n = 86
Ensembl frequencies
%, 1000 genomes
ExAC frequencies
%, n > 100,000
Exome Variant
Server frequencies
%, n > 12,000 P value
50UTR rs35667555 c.-37C>A C 98.8 A 1.2 C 99.6 A 0.4 C 98.7 A 1.3 – – n.s.
E03 rs2306386 c.132A>G (p.=) A 74.4 G 25.6 A 42.5 G 57.5 A 44.5 G 55.5 A 44.9 G 55.1 <0.0001
rs35198096 c.161A>G
(p.(Gln54Arg))
A 98.8 G 1.2 A 99.1 G 0.9 G 99.5 G 0.5 A 99.5 G 0.5 n.s.
I03 rs565610567
(C/A/T)
c.213+10C>G* C 98.8 G 1.2 – – – – – – –
rs2721189 c.213+82G>T G 80.2 T 19.8 G 5.2 T 94.8 – – – – <0.0001
E04 rs200516441 c.275C>T
(p.(Ser92Phe))
C 97.7 T 2.3 C 99.0 T 1.0 C 99.8 T 0.2 C 99.5 T 0.5 n.s.
rs4251688 c.309G>A (p.=) G 98.8 A 1.2 G 99.6 A 0.4 G 99.3 A 0.7 G 99.6 A 0.4 n.s.
I04 rs35058172 c.355-24G>C G 98.8 C 1.2 G 98.8 C 1.2 G 99.6 C 0.4 G 99.1 C 0.9 n.s.
E05 rs34159914 c.543G>A (p.=) G 97.7 A 2.3 G 99.9 A 0.1 G 99.6 A 0.4 G 99.6 A 0.4 n.s.
rs4244613 c.738C>T (p.=) C 79.1 T 20.9 C 63.0 T 37.0 C 56.1 T 43.9 C 66.1 T 33.9 0.011
rs4244612 c.801G>C
(p.(Glu267Asp))
G 80.2 C 19.8 G 55.2 C 44.8 G 56.2 C 43.8 G 60.8 C 39.2 0.0002
I06 rs34437789 c.1258+6A>T A 96.5 T 3.5 A 98.5 T 1.5 A 97.5 T 2.5 A 97.4 T 2.6 n.s.
rs4251689 c.1258+18G>A G 84.9 A 15.1 G 59.9 A 40.1 G 52.8 A 47.2 G 63.5 A 36.5 <0.0001
I07 rs766263452 (C/T) c.1391-6C>A* C 98.8 A 1.2 – – – – – – –
E09 rs754735053 c.1568G>C
(p.(Ser523Thr))*
G 98.8 C 1.2 – – G 99.97 C 0.03 – – –
I09 rs4244611 c.1621-15C>T C 72.1 T 27.9 C 60.5 T 39.5 C 52.0 T 48.0 C 64.9 T 35.1 n.s.
I10 rs35876881 c.1704+9C>T C 97.7 T 2.3 C 99.7 T 0.3 C 99.8 T 0.2 C 99.7 T 0.3 n.s.
I11 c.1878+22G>A* G 98.8 A 1.2 – – – – – – –
rs35126141 c.1879-15C>A C 97.7 A 2.3 C 98.9 A 1.1 C 99.7 A 0.3 C 99.1 A 0.9 n.s.
I13 rs200942592 c.2201-8C>T* C 98.8 T 1.2 – – C 99.99 T 0.01 – – n.s.
E14 rs35215952 c.2238G>A (p.=) G 98.8 A 1.2 G 99.0 A 1.0 G 99.6 A 0.4 G 99.2 A 0.8 n.s.
rs34293591 c.2395G>A
(p.(Val799Met))
G 98.8 A 1.2 G 99.4 A 0.6 G 98.2 A 1.8 G 98.3 A 1.7 n.s.
I14 c.2464-21C>A* C 98.8 A 1.2 – – – – – – –
E17 rs4251691 c.3014G>A
(p.(Arg1005Gln))
G 66.3 A 33.7 G 61.6 A 38.4 G 53.9 A 46.1 G 65.8 A 34.2 n.s.
I18 rs4244610 c.3236+13C>T C 70.9 T 29.1 C 56.7 T 43.3 C 49.4 T 50.6 C 60.7 T 39.3 0.0211
rs780188311 c.3237-20T>G* T 98.8 G 1.2 – – >T 99.99 <G 0.01 – – –
I19 rs756627 c.3393+8C>T C 70.9 T 29.1 C 59.9 T 40.1 C 53.3 T 46.7 C 65.0 T 35.0 n.s.
rs4251692 c.3393+9A>G A 97.7 G 2.3 A 99.3 G 0.7 A 97.7 G 2.3 A 98.7 G 1.3 n.s.
E20 rs61755066 c.3435G>C
(p.(Gln1145His))
G 98.8 C 1.2 G 99.9 C 0.1 G 99.7 C 0.3 G 99.7 C 0.3 n.s.
I20 rs2279243 c.3502+24G>A G 81.6 A 18.6 G 60.7 A 39.3 G 55.6 A 46.4 G 65.4 A 34.6 0.0012
E21 rs201384843 c.3609C>T (p.=) C 97.7 T 2.3 C 99.9 T 0.1 C 99.7 T 0.3 C 99.8 T 0.2 n.s.
USB1
exon (E)
intron (I) dpSNP ID Variant
Frequencies %,
n = 62
Ensembl frequencies
%, 1000 genomes
ExAC frequencies
%, n > 100,000
Exome Variant
Server frequencies
%, n > 12,000 P value
E01 rs3743559 c.42C>A (p.=) C 93.6 A 6.4 C 93.9 A 6.1 C 89.8 A 10.2 – – n.s.
I01 rs3743561 c.99-32A>T A 96.8 T 3.2 A 93.9 T 6.1 A 93.0 T 7.0 – – n.s.
rs18714585 c.99-34T>A T 96.8 A 3.2 T 93.9 A 6.1 T 93.9 A 6.1 – – n.s.
rs3743560 c.99-36G>A G 30.7 A 69.3 G 43.2 A 56.8 G 43.2 A 56.8 – – n.s.
I04 rs4784022 c.504-60C>T C 83.9 T 16.1 C 50.2 T 49.8 – – – – <0.0001
I06 rs16959640 c.693+15C>T C 96.8 T 3.2 C 91.1 T 8.9 C 97.2 T 2.8 – – n.s.
(Continued)
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variants including 5 frameshift, 3 in-frame, 1 nonsense
and 1 missense mutations have not been reported so far.
In summary, the RECQL4 mutation spectrum of our
patient cohort spreads almost all over the gene with the
exception of exons 1, 2, 4, 7, 8, 11, and 20 and is
represented by 1 splicing, 7 nonsense, 13 frameshift, 4
in-frame, and 6 missense mutations.
In addition to primarily disease causing mutations, we
detected 31 different variants in 8 exons and 12 introns
of the RECQL4 gene including 14 well known polymor-
phisms, 10 likely benign variants and 7 variants of
unknown significance (VUS) (Table 1). Four intronic
variants (c.213+10C>G, c.1391-6C>A, c.1878+22G>A,
c.2464-21C>A) have not been described before and are
not listed in any of the databases that have been checked
for these positions. Allele frequencies of our patient
cohort were compared with data from the SNP databases
1000 genomes, Exome Variant Server and ExAC Browser
and significant differences between frequences were found
for 3 exonic and 4 intronic variants (Table 1).
Clinical data from 12 out of 13 patients with two
mutations identified in the RECQL4 gene are summarized
in Table 2. From one patient no clinical data were avail-
able. Besides poikiloderma or other skin lesions (100%),
growth retardation and skeletal manifestations are the
second (83%) and third (75%) most common features
consistent with the diagnosis of RTS type II. The only
patient with two missense mutations shows a much
milder phenotype than all the other patients presenting
with poikiloderma as the sole symptom.
USB1 analyses
Sequencing of the USB1 gene in 31 patients with only
one or no detectable RECQL4 mutation identified eight
known polymorphisms (Table 1), but no pathogenic
mutation. However, in the only patient presenting with
typical clinical symptoms of PN we detected homozygos-
ity for a novel frameshift mutation c.334_335dupC
(p.(Arg112Profs*31)) in exon 3 leading to a premature
stop codon before the second H-X-S motif (Colombo
et al. 2012). The phenotype of this patient was character-
ized by poikiloderma, neutropenia, short stature, hypogo-
nadotropic hypogonadism (on hormonal replacement
therapy) and noncaseating granuloma involving the lungs
with interstitial lung disease and bronchiectasis.
Discussion
To date, 76 different mutations of the RECQL4 gene have
been reported in the Human Gene Mutation Database
(HGMD). Our study adds another 10 mutations that have
not been described so far (Fig. 1). The nonsense mutation
c.1222C>T (p.(Gln408*)) as well as the four frameshift
mutations c.558_564dupAGATCCT (p.(Gly189Argfs*11)),
c.2085delA (p.(Lys695Asnfs*148)), c.2277dupC (p.(Phe7
60Leufs*49)) and c.3008_3009delTG (p.(Val1003A-
lafs*29)) are assumed to result in a truncated protein,
whereas the frameshift mutation c.3330dupA
(p.(Glu1111Argfs*116)) causes an elongation of the gene
product by 17 amino acids. The three in-frame mutations
c.1930_1935dupGCCACA (p.(Ala644Thr645dup)), c.25
69_2574dupTGCACC (p.(Cys857_thr858dup)) and c.27
89_2812del24 (p.(His930_Leu937del)) have been pre-
dicted to be deleterious by the software tool Provean. The
results from different in silico analyses were somewhat
conflicting for the missense mutation p.(Ser1191Arg).
PredictSNP and MutPred predict this change to be delete-
rious, whereas PolyPhen-2 and SNPs&GO propose a
neutral state. Five of these novel mutations (4 truncating,
1 in-frame) are localized before or in the conserved
helicase domain (exons 8–14) shared by the other RecQ
helicases and are thought to destroy or disturb the DNA
helicase activity of RECQL4. The remaining five muta-
tions (2 frameshift, 2 nonsense, 1 missense) downstream
of the helicase domain may result in a loss or reduction
of the RECQL4 repair function and maintenance of
genome integrity. However, further studies such as tran-
Table 1. Continued.
USB1
exon (E)
intron (I) dpSNP ID Variant
Frequencies %,
n = 62
Ensembl frequencies
%, 1000 genomes
ExAC frequencies
%, n > 100,000
Exome Variant
Server frequencies
%, n > 12,000 P value
I06 rs12102539 c.694-114G>A G 96.8 A 3.2 G 98.3 A 1.7 – – – – n.s.
E07 rs16959641 c.748C>G
(p.(Gln250Glu))
C 96.8 G 3.2 C 94.0 G 6.0 C 93.0 G 7.0 – – n.s.
n.s., not significant.
GenBank accession numbers: RECQL4 NM_004260.3, USB1 NM_024598.3.
Bold characters: novel variants identified in this study.
Italic characters: significant (P values < 0.05, based on two-sided comparisons) differences in allele frequencies.
*Variant of unknown significance (VUS).
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script analyses and functional experiments are needed to
characterize the effect of these novel RECQL4 mutations.
In our study, we identified 18 patients (42%) with
RECQL4 mutations confirming the diagnosis of RTS II.
One patient presented with three mutations, the frame-
shift mutation c.1573delT (p.(Cys525Alafs*33)) in cis with
the amino acid substitution c.1568G>C (p.(Ser523Thr))
and the nonsense mutation c.2269C>T (p.(Gln757*)) in
trans. The c.1568G>C (p.(Arg112Profs*31)Ser523Thr)
variant is not yet listed in the SNP database but has been
described in association with c.1573delT (p.(Cys525A-
lafs*33)) by other authors (Siitonen et al. 2009). In five
patients only one RECQL4 mutation was detectable sug-
gesting that the second mutation has been missed by gene
sequencing such as large deletions/duplications or is local-
ized in gene regions that have not been analyzed (e.g.,
promoter, introns 3, 4, 6, 9, 12). As Piard et al. (2015)
identified no large rearrangements in 29 patients with
suspected RTS and only one RECQL4 mutation or nega-
tive RECQL4 sequencing by array-CGH analysis, we
believe that large deletions or duplications may occur
rarely in RTS patients and that the focus of further analy-
ses should be on promoter and intronic mutations as well
as on other candidate genes.
Because PN is a possible differential diagnosis in the
presence of poikiloderma, we sequenced the USB1 gene in
all patients with only one or no RECQL4 mutation and
in one patient with poikiloderma and neutropenia. We
detected homozygosity for the novel mutation
c.334_335dupC (p.(in the latter, but no pathogenic muta-
tion in the other patients leading to the conclusion that
mainly patients with a phenotype of poikiloderma and
neutropenia are candidates for USB1 mutation screening.
In other respects, there is no distinct genotype-phenotype
correlation, particularly not with regard to specific muta-
tions. In summary, we can state from Table 2 that the
patient the with two missense mutations (9) tends to a
milder phenotype with the only symptom of poikilo-
derma at the time of genetic analysis and that patients
with two truncating mutations (No 8, 12, 13, 15, 17, 18,
19) show all skin, skeletal and/or growth abnormalities.
In addition, patient No 15, carrying the novel nonsense
mutation c.1222C>T (p.(Gln408*)) and the known non-
sense mutation c.1078C>T (p.Gln360*)), has developed
several squamous cell carcinomas (SCC) and basal cell
carcinoma.
Besides of pathogenic mutations, we identified 31
RECQL4 and 8 USB1 variants and found statistically signifi-
cant differences for seven (c.132A>G, c.213+82G>T,
c.738C>T (p.=), c.801G>C (p.=), c.1258+18G>A,
c.3236+13C>T, c.3502+24G>A) and one (c.504-60C>T) of
them respectively compared to population frequencies of
Exome Variant Server and 1000 genomes databases
(Table 1). The relevance of these findings is not yet clear. A
disease association of these variants has been excluded as
our patient cohort carries more wildtype alleles than the
populations of the databases. This phenomenon needs
further evaluation in order to determine if it is just the
result of a very small patient number or if it is a fact either
representing different ethnic background or even a protec-
tive effect of specific RECQL4 and/or USB1 sequence
changes. Moreover, we detected four novel intronic
RECQL4 variants, one of them (c.1878+22G>A) in a
patient with one truncating mutation and no second
known mutation. This variant is worth testing on transcript
level, as the RECQL4 gene is known to have a specific splic-
ing pattern based on the short size of 13 of its introns
(Colombo et al. 2014).
The current study presents novel mutations and sum-
marizes neutral variants of the RECQL4 and USB1
genes contributing to the improvement of data inter-
pretation and diagnostic strategies in patients with sus-
picion of the very rare genodermatoses Rothmund–
Thomson disease and poikiloderma with neutropenia.
In case of unclear or negative findings gene sequencing
should be accompanied by transcript analysis that, how-
ever, requires EBV-transformed lymphoblastoid cell
lines, cell cultures or fresh tissue for RNA isolation.
The identification and characterization of RECQL4
mutations is relevant in order to assess the patients’
cancer risk, to avoid extensive and inconclusive clinical
evaluations and to clarify the recurrence risk in the
families. Our findings show, however, that the pheno-
type of more than 50% of the patients with suspected
Rothmund–Thomson disease may be due to mutations
in other genes raising the need for further extended
genetic analyses.
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